Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Natalia Lazorko"'
Autor:
Tamara Chitanava, Iuliia Matvienko, Vasily Shuvaev, Sergey Voloshin, Irina Martynkevich, Yulia Vlasova, Elizaveta Efremova, Ekaterina Mileeva, Anna Pirkhalo, Taiana Makarova, Roman Vlasik, Elena Karyagina, Natalia Il`ina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Nadia Siordiya, Olga Kulemina, Evgenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Dmitrii Motorin, Elena Morozova, Elza Lomaia
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionTyrosine kinase inhibitor (TKI) therapy has greatly improved the prognosis of patients with chronic myeloid leukemia (CML), improving the survival expectancy of patients with chronic phase (CP) CML to that of the general population. Howev
Externí odkaz:
https://doaj.org/article/3f73727d932e494ca05845597428ce8a
Autor:
Elza Lomaia, Tamara Chitanava, Yulia Vlasova, Dmitry Motorin, Sergey Voloshin, Darina Zammoeva, Renat Badaev, Yulia Matvienko, Elizaveta Efremova, Ekaterina Mileeva, Nadia Siordia, Olga Kulemina, Eugenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Irina Martynkevich, Elena Karyagina, Natalia Ilyina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Svetlana Stepanova, Vasily Shuvaev, Elena Morozova
Publikováno v:
Blood. 140:12192-12193
Autor:
Tamara Chitanava, Vasily Shuvaev, Iuliia Matvienko, Irina Martynkevich, Sergey Voloshin, Elizaveta Efremova, Ekaterina Mileeva, Mikhail Fominykh, Anna Kersilova, Elena Koryagina, Natalia Ilyina, Natalia Dorofeeva, Nadezhda Medvedeva, Anna Klimovich, Tatiana Shneider, Svetlana Stepanova, Natalia Polezhajkovskaya, Nadiya Siordiya, Eugenia Sbityakova, Natalia Lazorko, Elena Tochenaya, Dmitry Motorin, Nadezhda Shnalieva, Yulia Alekseeva, Darina Zammoeva, Elza Lomaia
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S288
Autor:
Tamara Chitanava, Agniia-Polina Poshivay, Andrey Zaritskey, Vasily Shuvaev, Nadezhda Shnalieva, Darina Zammoeva, Mikhail Fominykh, Irina Martynkevich, Natalia Polezhajkovskaya, NT Siordiya, Eugenia Sbityakova, Anna Kersilova, Elena Koryagina, Nadezhda Medvedeva, Elena Tochenaya, Svetlana Stepanova, Natalia Ilyina, Elza Lomaia, Natalia Lazorko, Elizaveta Efremova, Olga Merzlikina, Anna Klimovich, Tatiana Shneider, Natalia Dorofeeva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S242
Context Tyrosine kinase inhibitors in third-line therapy (TKI-3L) in chronic-phase chronic myelogenous leukemia (CP CML) is effective in a portion of patients. Meanwhile, it is unclear which patients may benefit from TKI-3L. Objective To identify the
Autor:
Natalia Ilina, Elza Lomaia, Aleksei Titov, Nadia Siordia, Andrey Zaritskey, Natalia Lazorko, Ekaterina Ovsyannikova, Dmitry Motorin, Darina Zammoeva, Diana Babenetskaya, Renat Badaev
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:S227
Autor:
Elena Machyulaitene, Mikhail Fominykh, Irina Martynkevich, Evgenia Salamatova, Elza Lomaia, Kudrat Abdulkadyrov, Vasily Shuvaev, Pavel Butylin, Andrey Zaritskey, Natalia Matyuhina, Ekaterina Ovsyannikova, Natalia Lazorko
Publikováno v:
Blood. 126:4051-4051
Introduction. Overall survival (OS) of patients in chronic phase (CP) chronic myeloid leukemia (CML) dramatically increased in the era of tyrosine kinase inhibitors (TKI). Meanwhile nearly half of patients discontinue 1-st line Imatinib due to resist
Autor:
Diana Mescheryakova, Eugenia Sbityakova, Vladimir Strugov, Ekaterina Romanova, Nadia Siordia, Elza Lomaia, Andrey Zaritskey, Tatiana Silina, Elena Goriunova, Larisa Girshova, Yulia Alexeeva, Dmitry Motorin, Natalia Lazorko
Publikováno v:
Blood. 122:5173-5173
Dramatic changes in overall survival of patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) have occurred since tyrosine kinase inhibitors (TKIs) were implemented in the treatment strategy. But there are still many issues in ther
Autor:
Irina Martinkevich, Natalia Ilina, Andrey Zaritskey, Elena Karyagina, Natalia Lazorko, Elza Lomaia, Elena Usacheva, Vera Udalieva, Ekaterina Romanova, Irina Zotova, Tatiana Shneider, Eugenia Sbityakova, Alla Abdulkadyrova, Vasiliy Shuvaev, Kudrat Abdulkadyrov, Elena Machulaitene, Irina Kholopova
Publikováno v:
Blood. 120:4432-4432
Abstract 4432 Background: The incidence of chronic myeloid leukemia (CML), reported from some population based registries, varies significantly. CML is known as age-dependent disease, so population age structure may strongly influent on the data. For
Autor:
Elena Koryagina, Irina Zotova, Elza Lomaia, Natalia Ilina, Vasiliy Shuvaev, Andrey Zaritskey, Zvenyslava Masliak, Irina Dyagil, Natalia Lazorko, Natalia Babkina, Irina Dmitrenko, T. Perekhrestenko, Elena Machulaitene, Svetlana Stepanova, Ekaterina Poznyak, Elena Usacheva, Kudrat Abdulkadirov, Irina Martinkevich, Eugenia Sbityakova, Ekaterina Romanova, Alla Abdulkadirova, Elena Goryunova, Maria Ivanova, Vera Udalieva, Tatiana Shneider
Publikováno v:
Blood. 118:4452-4452
Abstract 4452 Imatinib (IM) is now used world-wide as a first line chronic myeloid leukemia (CML) treatment. Although some time lack may exist between diagnosis and IM treatment. Earlier (Blood 2009, 114: Abstract 4278) we have shown that in CML chro
Autor:
Dgariyat Shikhbabaeva, Elza Lomaia, Elena Usacheva, Ekaterina Romanova, Elena Machulaitene, Natalia Ilina, Irina Martynkevich, Alla Abdulkadyrova, Vasiliy Shuvaev, Evgenia Salamatova, Kudrat Abdulkadyrov, Irina Zotova, Tatiana Shneider, Vera Udalieva, Ekaterina Poznyak, Maria Ivanova, Natalia Lazorko, Elena Koryagina, Svetlana Stepanova, Andrey Zaritskey
Publikováno v:
Blood. 116:4476-4476
Abstract 4476 At present, the main goal of chronic myeloid leukemia (CML) therapy is to obtain complete cytogenetic response (CCyR) which is strongly associated with patient's survival. The second main factor for good prognosis after CCyR achievement